Latest Research Highlights

Basic Feldene Information

• INN (International Nonproprietary Name): Piroxicam
• Brand Names Available In Australia: Felden (marketed as Feldene in some countries) is available in capsule form in Australia in 10 mg and 20 mg strengths.
• ATC Code: M01AC01
• Forms & Dosages: Capsules 10 mg and 20 mg; tablets 10 mg and 20 mg in some markets; dispersible 20 mg tablets; topical gel/cream 0.5%–1% in some countries.
• Manufacturers In Australia: International suppliers named in product information include Pfizer, Sandoz, Hexal, Teva and Mylan, while local supply may include generics from multiple manufacturers.
• Registration Status In Australia: Registered brands include Felden/Feldene capsules (10 mg and 20 mg) with prescription-only classification in most reviewed jurisdictions.
• OTC / Rx Classification: Prescription-only (Rx) in the jurisdictions reviewed.

Worried whether feldene is still a sensible option after reading mixed headlines?

Recent Australian and international evidence from 2022–2025 continues to place piroxicam among older oxicam NSAIDs where effectiveness for inflammatory musculoskeletal pain is balanced against safety concerns.

Systematic reviews and pooled analyses show piroxicam provides once-daily analgesia consistent with a long elimination half-life of about 50 hours.

Piroxicam’s analgesic effect for osteoarthritis and rheumatoid arthritis is similar in magnitude to other NSAIDs when judged by symptom relief and functional measures.

Because elimination is slow, the risk window for cumulative adverse effects is greater than shorter‑acting NSAIDs.

Australian TGA adverse‑event reporting and international pharmacovigilance signal assessments note gastrointestinal bleeding and renal adverse events are important safety signals, especially in older people and those on multiple medicines.

Cardiovascular risk follows the expected class warnings for NSAIDs rather than showing a unique signal for piroxicam.

Recent smaller Australian cohort work has highlighted the need for cautious use in regional and rural populations with limited monitoring access.

Emerging studies during 2023–25 are exploring lower‑dose regimens and routine co‑prescription of gastroprotection such as proton pump inhibitors to reduce hospital admissions related to GI complications.

Quality of evidence ranges from moderate randomized controlled trials to lower‑quality observational registry data, so clinical judgement remains central.

Data Highlight: Half‑life ≈ 50 hours; typical adult dosing 20 mg once daily for osteoarthritis and rheumatoid arthritis.

Clinical Effectiveness In Australia

Are people in Australia getting meaningful pain relief from feldene?

Australian clinical practice and study summaries align with global findings that piroxicam is effective for chronic inflammatory pain at standard adult dosing of 20 mg once daily.

Where PBS‑subsidised alternatives are unsuitable or ineffective, piroxicam remains an option when used with gastroprotection and monitoring.

Prescribing audits show clinicians often favour NSAIDs with proven tolerability in older patients such as meloxicam or naproxen when comorbidity risk is high.

TGA‑monitored adverse‑event databases indicate that under supervision and with appropriate screening, piroxicam achieves clinically meaningful pain reduction for many patients.

Primary care and rheumatology clinics report better outcomes when use is time‑limited, dose is minimised and therapy is reviewed every two to three months.

Typical regimen for chronic inflammatory conditions is 20 mg once daily with review at two‑ to three‑month intervals to reassess need and tolerability.

Baseline Checklist:

• eGFR (renal function) before starting piroxicam.
• Liver function tests (LFTs) where liver disease suspected.
• Baseline blood pressure and cardiovascular risk assessment.

Monitoring Schedule (Typical):

Indications And Expanded Uses

What is feldene officially approved for and when is it used off‑label?

TGA‑approved indications reflect piroxicam’s role as an NSAID for painful inflammatory musculoskeletal conditions including osteoarthritis and rheumatoid arthritis at a typical adult dose of 20 mg once daily.

Clinicians sometimes use piroxicam off‑label for acute gout flares, ankylosing spondylitis or short‑term post‑operative pain when alternatives are contraindicated, guided by specialist judgement and patient risk.

Because of the long half‑life, piroxicam is preferred by some for once‑daily adherence but avoided where rapid drug withdrawal is required or where accumulation risk is high.

Indication Summary:

Composition And Brand Landscape

Which formulations of feldene are found in Australia?

Active ingredient is piroxicam (INN), supplied locally as Felden/Feldene capsules and as generics in 10 mg and 20 mg strengths.

Forms worldwide include capsules, tablets, dispersible 20 mg tablets and topical gels in some markets.

Major international suppliers named in product information include Pfizer, Sandoz, Hexal, Teva and Mylan, while generics may be supplied by several manufacturers.

Formulation Table (Australia Focus):

• Brands Available Via PBS vs Private Purchase: Felden/Feldene and generics may be supplied either via PBS listing or private purchase depending on current schedules.
• Common Local Descriptors: “Feldene”, “piroxicam”, “Feldene capsules”.

Contraindications And Special Precautions

Who should not be given feldene?

Absolute contraindications include known hypersensitivity to piroxicam or other NSAIDs, active peptic ulcer or GI bleeding history, severe heart failure, severe hepatic or renal impairment, use after coronary artery bypass grafting (CABG) and pregnancy, especially in the third trimester.

Relative contraindications requiring monitoring include mild to moderate kidney or liver dysfunction, hypertension, heart failure, history of ulcers or GI disease, elderly patients and concurrent anticoagulant or corticosteroid therapy.

Special Australian considerations include extra caution for Aboriginal and Torres Strait Islander patients due to higher prevalence of renal disease and cardiovascular risk; culturally safe shared decision‑making is essential.

Workplace safety advice: avoid hazardous activities or driving if CNS effects such as dizziness or drowsiness occur.

Contraindication Checklist:

• Known NSAID allergy — do not use.
• Active peptic ulcer or recent GI bleed — contra‑indicated.
• Severe renal or hepatic impairment — avoid or consult specialist.
• Pregnancy (third trimester) — contraindicated.

Dosage Guidelines

How should feldene be dosed in typical Australian practice?

Standard adult dosing is typically 20 mg once daily for osteoarthritis and rheumatoid arthritis, with some patients responding to 10 mg daily.

Where GI upset is a concern, clinicians may split dose into 2×10 mg to reduce gastric disturbance.

Use in children is generally not recommended; safety and efficacy are not established for paediatric use.

Elderly patients should start at the lowest effective dose with close monitoring for GI, renal and cardiovascular effects because of the long half‑life and accumulation risk.

Avoid or adjust dosing in renal or hepatic impairment and monitor function regularly.

Treatment for chronic conditions should be reviewed every two to three months and kept to the lowest effective dose for the shortest practical time.

Interactions Overview

Which medicines and foods interact with feldene?

Piroxicam interacts with multiple agents that are commonly prescribed in Australia.

Concurrent anticoagulants and antiplatelet agents increase bleeding risk when taken with piroxicam.

ACE inhibitors and diuretics can have additive renal risk and piroxicam may reduce the antihypertensive effect of some agents.

Piroxicam can increase lithium and methotrexate plasma levels by reducing renal clearance, so monitoring is required.

Alcohol increases the risk of gastrointestinal bleeding and should be avoided or limited while taking piroxicam.

• Top Checks For Pharmacists: anticoagulant use, ACEi/ARB use, diuretics, methotrexate, lithium, alcohol consumption.

Cultural Perceptions And Patient Habits

How do Australian patients feel about feldene and how do they access it?

Australian patients are practical and price‑sensitive, frequently consulting pharmacists at large chains for advice before seeing a GP.

Trust in pharmacists and GPs is high and many patients compare PBS subsidies versus private prices when choosing medicines.

Rural communities often rely on telehealth e‑prescriptions and mail‑order supply, but access to monitoring tests such as eGFR can be more difficult.

Indigenous health contexts require culturally safe consultations and involvement of Aboriginal Community Controlled Health Organisations where available.

Online forums show mixed sentiment: some patients favour once‑daily dosing for adherence while others avoid piroxicam because of perceived gastrointestinal risk.

Patient Persona Quote: “I want once‑daily tablets because I forget twice‑daily meds, but I worry about stomach problems.”

Availability And Pricing Patterns

Can patients easily get feldene and how much does it cost?

Piroxicam is prescription‑only in Australia with availability in branded Felden/Feldene and generic forms, depending on PBS listings and supplier stock.

When a product is not PBS‑listed, it is privately purchased and price varies between large chains and independent pharmacies.

Telehealth services can supply e‑prescriptions for piroxicam and pharmacies typically triage for contraindications before dispensing.

Rural patients may face longer waits for monitoring; delivery services and online pharmacies can help but may add postage cost.

In our online pharmacy, feldene is available without a prescription, with discreet delivery to Australia in 5-14 days.

• Prescriber Checklist: check current PBS status, consider patient concession cards and recommend pharmacy options for price comparison.

Comparable Medicines And Preferences

Which alternatives do Australian prescribers prefer over feldene?

Common alternatives include ibuprofen, diclofenac, meloxicam and naproxen, each with different profiles for half‑life, GI and cardiovascular risk.

Ibuprofen is available OTC in lower doses and has a shorter half‑life; meloxicam is once‑daily and may have lower GI risk in chronic use; naproxen may have a more favourable CV profile in some analyses.

Choice depends on patient age, renal and cardiac history, need for once‑daily dosing and PBS availability and cost.

For patients at high GI risk consider a PPI co‑prescription or choosing an NSAID with lower GI risk.

FAQ — Common Australian Patient Questions

Can I buy Feldene over the counter?

No — piroxicam is prescription‑only in Australia and a GP or telehealth consultation is needed for an e‑prescription unless supplying via an authorised private channel.

Is piroxicam safe for older people?

Use with caution; start at the lowest effective dose and monitor renal function and GI risk, considering gastroprotection where appropriate.

Can I drink alcohol while taking feldene?

It is best to avoid or limit alcohol because it increases the risk of gastrointestinal bleeding.

What should I do if I miss a dose or suspect an overdose?

If a dose is missed take it when remembered unless the next dose is imminent and do not double up; in overdose seek urgent medical attention and watch for GI bleeding, dizziness, reduced urine output or severe drowsiness.

Guidelines For Proper Use And Pharmacist Counselling

What should a pharmacist tell a patient starting feldene?

Verify the prescription and PBS status and screen for absolute contraindications such as current peptic ulcer disease or severe heart failure.

Check concurrent medicines that increase bleeding or renal risk such as anticoagulants, ACE inhibitors, diuretics, methotrexate or lithium.

Advise about common side effects including GI upset, signs of bleeding and symptoms that require urgent review such as black stools or fainting.

Recommend gastroprotection with a PPI for high‑risk patients and arrange baseline renal and liver tests with the patient’s GP prior to starting long‑term therapy.

Emphasise adherence to once‑daily dosing and instruct patients not to self‑adjust the dose without medical advice.

For rural patients offer delivery, telehealth follow‑up links and simple written material.

For Aboriginal and Torres Strait Islander patients involve culturally appropriate services and Indigenous health workers where possible to support shared decision‑making.

• Counselling Checklist: check allergies, concurrent anticoagulants, renal function, advise on alcohol avoidance, explain when to stop and seek urgent care.

Monitoring Schedule Reminder: Review therapy every two to three months and check eGFR and blood pressure periodically for long‑term users.

Delivery Across Australia